Palo Santo VC — Full Portfolio

2AB BioscienceS develops first-in-class small molecule therapeutics targeting the 5-HT2A receptor for ophthalmology and central nervous system disorders.

BiotechDeep TechDigital HealthEdTechHealthtechMedical DevicesSanta Monica, US

ASAlex Speiser(Co-Founder & Chief Executive Officer)inCNCharles Nichols, PhD(Co-Founder & Chief Science Officer)DNDavid Nichols, PhD(Co-Founder & Head of Chemistry)Tim Foster, PhD(Co-Founder & Head of Translational Discovery)

BoardGopal Das(Director)

Co-investorsDEDecentraNetGAGaingelsLELeafy TunnelLILIONHEART VENTURESMYMystic VenturesTATabula Rasa Ventures+1 more

Atai Beckley develops rapid-acting, durable, and convenient therapies for mental health conditions where patients currently have limited treatment options.

BiotechDigital HealthMental Health

Co-investorsCACatalio Capital Management, LPDADaniel GutenbergNUNucleus Adventure CapitalP5P53 InvestPSPsyMed Ventures

AtaiBeckley develops rapid-acting and durable mental health treatments for patients with difficult-to-treat mental health conditions.

BiotechMedical DevicesMental Health

CAChristian AngermayerCFCosmo Feilding Mellen(Founder)inSRSrinivas Rao

Co-investorsBABailey Venture PartnersFJFJ LabsITIter InvestmentsLELeafy TunnelMAMaiora Rebel VenturesNONoetic+4 more

BRC Therapeutics develops and manufactures botanically-derived pharmaceutical products, with expertise spanning drug development and manufacturing for pharmaceutical applications.

BiotechDigital HealthHealthtechMedical Devices

George Hodgin(Founder and CEO)inCSCharles Schumacher

Co-investorsDEDelta Emerald Ventures

Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform.

BiotechDeep TechHealthtechNew York, US

Alan Kozikowski(Executive Officer, Director)inIan McDonaldRyan Cheung(Chief Financial Officer)JAN PEDERSEN(Chief Science Officer)Gideon Shapiro(Executive Officer)Revati Sheeniwas(Executive Officer)

Co-investorsLILifeSci Venture PartnersPSPsyMed Ventures

Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.

BiotechDigital HealthMedical Devices

David Olson(Founder)David Olson Nick Haft(Founder)Nick Haft(Founder)

Co-investorsARArtis VenturesBABailey Venture PartnersCACasa Verde CapitalDODolby Family VenturesGAGaingelsIAIaso Ventures+9 more

Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds.

BiotechHealthtechMental HealthToronto, CA

JBJudy Blumstock(Chief Executive Officer, Founder, Director)inMichael B. McDonnell(Chief Medical Officer)inGrant McCutcheon(Chief Financial Officer)in

Co-investorsJLJLSNONoeticNENew Enterprise Associates (NEA)NENextech InvestRARA Capital

Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.

AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US

LGLinda Goodman(Founder)inAshley(CEO)

Co-investorsAGage1BIBija VenturesFAFarvatn VentureGAGaingelsGRGRIDS CapitalLILifeforce Capital+9 more

Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.

AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US

JSJonathan Sporn(Founder)inAKAndrew Kruegel(Founder)inDSDalibor Sames(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Thomas Kevin Murphy, Ph.D.(Executive Officer)JSJONATHAN SPORN(Founder)in

Co-investorsAEAera VCALAlumni VenturesAWAwareness VentureFRFrontera Technology VenturesFRFrontier Path VCGAGaingels+27 more

Journey Clinical provides ketamine-assisted psychotherapy (KAP) for depression, anxiety, and PTSD, partnering patients with licensed therapists and medical teams while coordinating with major insurance providers.

Digital HealthMedical DevicesMental Health

JSJonathan Sabbagh(Founder)inMBMyriam Barthes(Founder)in

Co-investorsABAble PartnersALAlleyCorpCOCoalition OperatorsFIFifty YearsFJFJ LabsGAGaingels+9 more

Kadence Bio is a clinical-stage life sciences company developing therapeutics for conditions in sexual and mental health.

BiotechDigital HealthMental Health

Co-investorsUCUCEAVOVox Capital

Active seed-stage healthcare company

Eugene, US

Nicholas Allen(Chief Executive Officer)Phillip Scripa(Chief Financial Officer and Secretary)William Shortt(Chief Operating Officer)JHJan Hardorp(Director)in

Co-investorsBIBIP VenturesJLJLSWPWPSS InvestmentsREre.Mind Capital

Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety.

BiotechDeep TechHealthtechAllston, US

DDDario Doller(Co-founder)inKHKevin Hodgetts(Founding Lab / Co-founder)inAndrew Thomson(Executive Officer, Director, Promoter)in

Co-investorsPIPillar VCBIBija VenturesHEHealthspan Capital

MycoMedica Life Sciences is a biopharmaceutical company developing psilocybin-based treatments for mental health and neurodegenerative disorders.

BiotechDigital HealthMental HealthShelton, US

Co-investorsGAGaingelsLALauder PartnersOBObvious VenturesTRTrue Ventures

Pangea Bio develops therapies targeting central nervous system and mental health disorders by activating the TrkB receptor pathway to promote neuronal survival and synaptic plasticity.

BiotechDeep TechDigital Health

Co-investorsMEMetaplanetNONO LABEL VENTURESSESeaside VenturesVOVox CapitalXEXEIA Venture Partners

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.

BiotechDigital HealthMental HealthMorristown, US

Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)ELEllen Lubman(Director)MPMark Pollack(Executive Officer)inNBNathan Bryson(Executive Officer)inMTMark Theeuwes(Executive Officer)in

Co-investorsFEFemHealth VenturesMIMitsui Global InvestmentMPMPM BioImpactNONovo Holdings

Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.

AI & Machine LearningBiotechDigital HealthMedford, US

JRJerrold Rosenbaum(Co-Founder & Chair Emeritus, Massachusetts General Hospital (MGH) Department of Psychiatry)inJHJacob Hooker(Co-Founder & Chief Executive Officer)inPranav Tadi(Executive Officer)Stephen Haggarty, PhD(Co-Founder & Professor of Neurology, Harvard Medical School)Dick Simon, MBA(Co-Founder)

BoardRKRyan Katz(Director)in

Co-investorsBOBonaventure Equity, LLCCUCU Healthcare Innovation FundDODolby Family VenturesHAHatteras Venture PartnersITIter InvestmentsMIMission Biocapital+5 more

Syndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's.

AI & Machine LearningBiotechDigital HealthIndianapolis, US

Derek Small(Co-founder and Chief Executive Officer)

Co-investorsEVEvolution VC PartnersTETenmileCACatalio Capital Management

Tactogen develops patented new chemical entities, including benzofuran-based compositions, and conducts preclinical research and publishes data on these compounds.

BiotechDeep TechHealthtech

MBMatthew Baggott(CEO)in

Co-investorsGAGaingelsLELeafy TunnelNONoeticPSPsyMed Ventures1010X CapitalWEWefunder

Transcend Therapeutics develops rapid-acting pharmaceutical treatments for neuropsychiatric diseases, including PTSD and depression, targeting patients unresponsive to current psychiatric medications.

BiotechDigital HealthMedical DevicesMental Health

BMBlake Mandell(Co-Founder & CEO)in

Co-investorsALAlleyCorpALAlpha Wave GlobalALAlumni VenturesCOConcentricEMEmerald Development ManagersFJFJ Labs+2 more

Wavepaths develops adaptive therapeutic music designed to support mental health and wellness practitioners in their sessions.

Digital HealthMental HealthWellness & Fitness

MKMendel Kaelen(Founder & CEO)in

Co-investorsMIMITONREReflex CapitalTATabula Rasa VenturesEMEmpath VenturesLILIONHEART VENTURESNENeo Kuma Ventures

Xylo develops mechanism-based drug therapies targeting psychiatric and neurological disorders using computational and rational drug design approaches.

BiotechDeep TechDigital HealthHealthtechSydney, AU

Joshua Ismin(Co-founder, President)inDr. Sam Banister(Co-founder, Chief Scientific Officer)

Co-investorsMYMystic VenturesRARadar VenturesTETenmileXEXEIA Venture PartnersCACapitalTCOCommon Magic+1 more